Glow Nest Beauty
FDA issued a warning letter to Glow Nest Beauty (glownestbeauty.com) for selling unapproved and misbranded injectable botulinum toxin drug products, specifically 'Rentox 200U – Botulinum Toxin Type A,' to U.S. consumers without FDA approval or a prescription requirement. The site's product listing included drug-intent claims such as 'Excessive sweating (hyperhidrosis)' under 'Indications,' establishing the products as drugs under the FD&C Act. FDA cited violations of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the FD&C Act and demanded corrective action within 15 working days, warning that failure to comply may result in seizure or injunction.
Flagged claims (1)
Excessive sweating (hyperhidrosis)
Required actions (3)
FDA requests that www.glownestbeauty.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers.
Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence.
Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most medical spa / aesthetics sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker